310 related articles for article (PubMed ID: 28316250)
1. Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target.
Sparrow MP
Expert Opin Biol Ther; 2017 May; 17(5):613-621. PubMed ID: 28316250
[TBL] [Abstract][Full Text] [Related]
2. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB
Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy options for ulcerative colitis.
Chaparro M; Gisbert JP
Expert Opin Pharmacother; 2016 Jul; 17(10):1339-49. PubMed ID: 27240112
[TBL] [Abstract][Full Text] [Related]
4. [Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].
Rutka M; Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Molnár T
Orv Hetil; 2016 May; 157(18):706-11. PubMed ID: 27106726
[TBL] [Abstract][Full Text] [Related]
5. Golimumab for the treatment of ulcerative colitis.
Flamant M; Paul S; Roblin X
Expert Opin Biol Ther; 2017 Jul; 17(7):879-886. PubMed ID: 28472597
[TBL] [Abstract][Full Text] [Related]
6. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
Dignass AU; Siegmund B; Goertz R; Schneidewind G; Fanter L
Scand J Gastroenterol; 2019 Feb; 54(2):178-187. PubMed ID: 30735443
[TBL] [Abstract][Full Text] [Related]
7. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
[TBL] [Abstract][Full Text] [Related]
8. ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY.
Zacharias P; Damião AOMC; Moraes AC; Teixeira FV; Ludvig JC; Nones RB; Saad-Hossne R; Sassaki LY; Silva RPLD; Facchin L; Olandoski M; Kotze PG
Arq Gastroenterol; 2017 Dec; 54(4):321-327. PubMed ID: 28977114
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.
Zhang ZM; Li W; Jiang XL
Gut Liver; 2016 Mar; 10(2):262-74. PubMed ID: 26780088
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab: a review of its use in the treatment of patients with ulcerative colitis.
Burness CB; Keating GM
BioDrugs; 2013 Jun; 27(3):247-62. PubMed ID: 23580096
[TBL] [Abstract][Full Text] [Related]
11. The economics of adalimumab for ulcerative colitis.
Xie F
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):373-7. PubMed ID: 25817776
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
[TBL] [Abstract][Full Text] [Related]
13. Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis.
Beilman CL; Thanh NX; Ung V; Ma C; Wong K; Kroeker KI; Lee T; Wang H; Ohinmaa A; Jacobs P; Halloran BP; Fedorak RN
Can J Gastroenterol Hepatol; 2016; 2016():5315798. PubMed ID: 27781203
[No Abstract] [Full Text] [Related]
14. Adalimumab in ulcerative colitis: ready for prime time.
Danese S
Dig Liver Dis; 2013 Jan; 45(1):8-13. PubMed ID: 22766323
[TBL] [Abstract][Full Text] [Related]
15. Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab.
Armuzzi A; Pugliese D; Nardone OM; Guidi L
Drug Des Devel Ther; 2013; 7():289-96. PubMed ID: 23630414
[TBL] [Abstract][Full Text] [Related]
16. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
17. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
Feagan BG; Sandborn WJ; Lazar A; Thakkar RB; Huang B; Reilly N; Chen N; Yang M; Skup M; Mulani P; Chao J
Gastroenterology; 2014 Jan; 146(1):110-118.e3. PubMed ID: 24067881
[TBL] [Abstract][Full Text] [Related]
19. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis.
Kobayashi T; Udagawa E; Uda A; Hibi T; Hisamatsu T
J Gastroenterol Hepatol; 2020 Feb; 35(2):225-232. PubMed ID: 31397010
[TBL] [Abstract][Full Text] [Related]
20. [Biological agents in ulcerative colitis. When to prescribe].
Barreiro-de Acosta M
Gastroenterol Hepatol; 2011 Dec; 34 Suppl 3():36-42. PubMed ID: 25443225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]